[Google Scholar] Associated Data This section collects any data citations, data availability statements, or supplementary materials included in this article
The glucagon receptor activation is the key differentiator: it directly increases energy expenditure and fat oxidation through pathways completely independent of GLP-1 signaling
PMC 4108183
The efficacy and safety of the new GLP-1 medicines continues to garner interest and will be discussed #ADA2024 Here is an updated safety-focused summary of the field and where it might be headed @DiabetesCareADA #T2D #obesity pic.twitter.com/rtEQYtHQG0 Daniel J Drucker (@DanielJDrucker) June 6, 2024 Investigational GLP-1 medicines in the clinic Late-stage investigational GLP-1 medicines for type 2 diabetes and obesity include new molecules like retatrutide and orforglipron, showing potential differentiation from semaglutide and tirzepatide through better tolerability, greater weight loss, Hb A 1c reduction, and targeted outcomes
Instead of replacing hormones like estrogen and progesterone, GLP-1s mimic a natural gut hormone (called glucagon-like peptide-1) that helps control appetite, slow digestion, and balance blood sugar
Has anyone run a head-to-head trial of cagrilintide vs tirzepatide
